Annovis Bio Launches Phase 3 Alzheimer's Clinical Trial, Advances Research and Patent Portfolio

Annovis Bio Inc. has advanced its Alzheimer's research by launching a comprehensive Phase 3 clinical trial targeting early-stage Alzheimer's disease. The study, designed to enroll up to 760 participants, will evaluate the potential symptomatic and disease-modifying effects of the company's experimental drug buntanetap over an 18-month period.

The trial represents a critical milestone in neurological research, focusing on a treatment that could potentially address multiple aspects of Alzheimer's progression. By targeting multiple neurotoxic proteins, buntanetap aims to restore brain function and improve patients' quality of life, a significant goal in a field where effective treatments remain limited.

Concurrent with the trial launch, Annovis Bio has strengthened its research position by securing a new U.S. patent for buntanetap. The company has also increased its scientific visibility by participating in key industry conferences, including the Oppenheimer Annual Healthcare Life Sciences Conference and the AD/PD 2025 conference in Vienna.

Financial indicators suggest the company is maintaining strategic research investments while managing expenses. As of March 31, 2025, Annovis Bio reported cash and equivalents of $22.2 million, with research and development expenses decreasing year-over-year to $5.0 million. These financial metrics indicate a focused approach to advancing neurological treatment research.

The Phase 3 trial could represent a significant step forward in Alzheimer's treatment, potentially offering hope to millions affected by this progressive neurodegenerative condition. By exploring a novel approach that addresses multiple protein-related mechanisms, Annovis Bio is contributing to a broader understanding of potential intervention strategies in neurological disorders.